Resources from the same session
134MO - Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Presenter: Soo Hoo Hwoei Fen
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
135MO - Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Presenter: Yoon-Koo Kang
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
136MO - Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): East Asia subgroup of FIGHT final analysis
Presenter: Yoon-Koo Kang
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 134MO, 135MO and 136MO
Presenter: Hanneke van Laarhoven
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Webcast
138MO - Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
Presenter: Chia Jui Yen
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
139MO - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Presenter: Ken Kato
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session 2: Gastrointestinal tumours
Resources:
Webcast